Goldman Sachs Group Inc Biocryst Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,320,529 shares of BCRX stock, worth $17.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,320,529
Previous 2,530,259 8.29%
Holding current value
$17.6 Million
Previous $15.6 Million 12.78%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$6.41 - $8.69 $1.34 Million - $1.82 Million
-209,730 Reduced 8.29%
2,320,529 $17.6 Million
Q2 2024

Aug 13, 2024
BUY
$4.13 - $6.79 $2.5 Million - $4.11 Million
604,894 Added 31.42%
2,530,259 $15.6 Million
Q1 2024

May 15, 2024
BUY
$4.89 - $7.65 $736,487 - $1.15 Million
150,611 Added 8.49%
1,925,365 $9.78 Million
Q4 2023

Feb 13, 2024
BUY
$4.98 - $6.77 $1.16 Million - $1.57 Million
232,043 Added 15.04%
1,774,754 $10.6 Million
Q3 2023

May 14, 2024
SELL
$6.71 - $7.92 $1.56 Million - $1.84 Million
-232,043 Reduced 13.07%
1,542,711 $10.9 Million
Q3 2023

Nov 14, 2023
BUY
$6.71 - $7.92 $428,916 - $506,262
63,922 Added 4.32%
1,542,711 $10.9 Million
Q2 2023

May 14, 2024
BUY
$6.96 - $8.81 $2.45 Million - $3.1 Million
352,083 Added 31.25%
1,478,789 $10.4 Million
Q2 2023

Aug 14, 2023
BUY
$6.96 - $8.81 $2.45 Million - $3.1 Million
352,083 Added 31.25%
1,478,789 $10.4 Million
Q1 2023

May 14, 2024
SELL
$7.94 - $11.84 $39,604 - $59,057
-4,988 Reduced 0.44%
1,126,706 $9.4 Million
Q1 2023

May 11, 2023
SELL
$7.94 - $11.84 $39,604 - $59,057
-4,988 Reduced 0.44%
1,126,706 $9.4 Million
Q4 2022

May 14, 2024
SELL
$10.5 - $14.2 $3.54 Million - $4.79 Million
-337,461 Reduced 22.97%
1,131,694 $13 Million
Q4 2022

Feb 13, 2023
SELL
$10.5 - $14.2 $3.54 Million - $4.79 Million
-337,461 Reduced 22.97%
1,131,694 $13 Million
Q3 2022

May 14, 2024
BUY
$10.79 - $14.81 $997,459 - $1.37 Million
92,443 Added 6.71%
1,469,155 $18.5 Million
Q3 2022

Nov 10, 2022
BUY
$10.79 - $14.81 $997,459 - $1.37 Million
92,443 Added 6.71%
1,469,155 $18.5 Million
Q2 2022

May 14, 2024
SELL
$7.89 - $17.88 $3.14 Million - $7.12 Million
-398,042 Reduced 22.43%
1,376,712 $14.6 Million
Q2 2022

Aug 15, 2022
BUY
$7.89 - $17.88 $813,356 - $1.84 Million
103,087 Added 8.09%
1,376,712 $14.6 Million
Q1 2022

May 16, 2022
BUY
$11.56 - $19.76 $5.32 Million - $9.09 Million
459,965 Added 56.53%
1,273,625 $20.7 Million
Q4 2021

Feb 14, 2022
BUY
$11.18 - $15.46 $513,888 - $710,618
45,965 Added 5.99%
813,660 $11.3 Million
Q3 2021

Nov 10, 2021
BUY
$14.21 - $17.65 $10.9 Million - $13.5 Million
767,695 New
767,695 $11 Million

Others Institutions Holding BCRX

# of Institutions
278
Shares Held
172M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email